239 related articles for article (PubMed ID: 24031151)
1. New strategy for overcoming resistance to chemotherapy of ovarian cancer.
Kigawa J
Yonago Acta Med; 2013 Jun; 56(2):43-50. PubMed ID: 24031151
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.
Paley PJ
Curr Oncol Rep; 2002 Mar; 4(2):165-74. PubMed ID: 11822989
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
Gadducci A; Cosio S; Genazzani AR
Expert Rev Endocrinol Metab; 2007 Mar; 2(2):225-238. PubMed ID: 30754175
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer.
Suh DH; Kim MK; Kim HS; Chung HH; Song YS
J Cancer Prev; 2013 Sep; 18(3):227-34. PubMed ID: 25337550
[TBL] [Abstract][Full Text] [Related]
8. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Duan P; Fan L; Gao Q; Silwal BM; Ren M; Shen Y; Qu W
Curr Drug Targets; 2017; 18(10):1171-1178. PubMed ID: 28443505
[TBL] [Abstract][Full Text] [Related]
10. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistance in Ovarian Cancer: Prospects for New Drugs.
Tendulkar S; Dodamani S
Anticancer Agents Med Chem; 2021; 21(6):668-678. PubMed ID: 32900355
[TBL] [Abstract][Full Text] [Related]
13. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
14. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in ovarian cancer.
Willmott LJ; Fruehauf JP
J Oncol; 2010; 2010():740472. PubMed ID: 20130818
[TBL] [Abstract][Full Text] [Related]
16. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
Itamochi H
World J Biol Chem; 2010 Jul; 1(7):209-20. PubMed ID: 21537476
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
20. DNA-repair pathway inhibitors for the treatment of ovarian cancer.
Martinek I; Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2010 Jun; (6):CD007929. PubMed ID: 20556786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
